The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of alectinib in pediatric and adult patients with ALK altered advanced solid tumors: Results from the TACKLE phase II trial, a MASTER KEY substudy (NCCH1712/MK003).
 
Hitomi Okuma
No Relationships to Disclose
 
Ayumu Arakawa
Honoraria - Abbvie; Chugai Pharma; Lilly; Ohara Pharmaceutical; Ono Pharmaceutical
Research Funding - Chugai Pharma (Inst); Takeda (Inst)
 
Akihiro Hirakawa
Consulting or Advisory Role - Abbvie; Astellas Pharma; Chugai Pharma; Fuji Pharma; Kissei Pharmaceutical; Kyowa Kirin International; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Speakers' Bureau - Mitsubishi Tanabe Pharma; Pfizer; Takeda
 
Shinji Kohsaka
Research Funding - Boehringer Ingelheim (Inst); CMIC (Inst); Eisai (Inst); H.U. Group Research Institute (Inst); Konica Minolta (Inst)
 
Tomozo Yamada
No Relationships to Disclose
 
Kenta Anjo
Employment - Abbvie (I)
 
Kazumi Kurishita
No Relationships to Disclose
 
Kenichi Nakamura
Honoraria - Chugai Pharma; Taiho Pharmaceutical; Takeda
Research Funding - Astellas Pharma (Inst); Boehringer Ingelheim Seiyaku (Inst); Bristol-Myers Squibb Japan (Inst); Chugai/Roche (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Merck (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Pfizer (Inst); SERVIER (Inst); SymBio Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Shigemi Matsumoto
No Relationships to Disclose
 
Kenji Tsuchihashi
Honoraria - Bayer; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Merck; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Astellas Pharma
 
Ichiro Kinoshita
Honoraria - Bayer; Chugai Pharma; Guardant Health; Konica Minolta; MSD; Novartis; Pfizer; Takeda
Research Funding - Daiich Sankyo; Eisai; Konica Minolta
 
Kan Yonemori
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Eisai; Fujifilm; Lilly Japan; MSD Oncology; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Chugai Pharma; Eisai; EP biopharma; Haihe Pharmaceutical; Henlius; Novartis; OncXerna Therapeutics; Ono Pharmaceutical
Research Funding - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Eisai (Inst); Genmab (Inst); Haihe Pharmaceutical (Inst); Kyowa Hakko Kirrin (Inst); Lilly (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst)
 
Yasushi Goto
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Daiichi Sankyo/Astra Zeneca; Daiichi Sankyo/UCB Japan; Guardant Health AMEA; Janssen; Lilly Japan; Merck; MSD; Nichiiko; Novartis; Ono Pharmaceutical; Pfizer; Sandoz; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo/UCB Japan; Guardant Health AMEA; Janssen; Lilly; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Amgen BioPharama (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); CMIC (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo/UCB Japan (Inst); EP Croit Co. (Inst); EPS Holdings (Inst); Genomic Health (Inst); IQvia (Inst); Janssen (Inst); Lilly Japan (Inst); Medpace (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Preferred Network (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
(OPTIONAL) Uncompensated Relationships - Cancer Net Japan; JAMT